Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients

Clinical Chemistry

Volumn 44, Issue 9, 1998, Pages 1942-1946

  Cogill, Jan L ^a   Taylor, Paul J ^a,c   Westley, Ian S ^b   Morris, Raymond G ^b   Lynch, Stephen V ^a   Johnson, Anthony G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MICROPARTICLE ENZYME IMMUNOASSAY;

EID: 0031781987     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.9.1942     Document Type: Article

References (26)

1. Steinmuller DR. FK506 and organ transplantation. Boca Raton, FL: CRC Press, 1994:19-74.
2. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-96.
3. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zybler-Katz E, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995;17:606-14.
4. Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, et al. A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 1987;5(Suppl 6):23-9.
5. Wallemacq PE, Firdaous I, Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem 1993;39:1045-9.
6. D'ambrosio R, Jusko WJ, Stabler T, Kobayashi M. Improved procedures for enzyme immunoassay for tacrolimus (FK506) in whole blood [Letter]. Clin Chem 1994;40:159-60.
7. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991;23:2748-9.
8. Holt DW, Johnston A. Tacrolimus quality assessment [Letter]. Ther Drug Monit 1997;19:243.
9. Iwasaki K, Shiraga T, Nagase Z, Tozuka Z, Noda K, Sakuma S, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 1993;21:971-7.
10. Iwasaki K, Shiraga T, Matsuda H, Nagase K, Tokuma Y, Hata T, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidised at multiple sites of FK506. Drug Metab Dispos 1995;23:28-34.
11. Gonschior A-K, Christians U, Braun F, Winkler M, Linck A, Baumann J, Sewing K-F. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol 1994;38:567-71.
12. Warty V, Zuckerman S, Venkataramanan R, Lever J, Chao J, Mckaveney T, et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit 1995;17:159-67.
13. Firdaous I, Hassoun A, Otte JB, Reding R, Squifflet JP, Besse T, Wallemacq PE. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. Clin Chem 1995;41:1292-6.
14. Braun F, Lorf T, Schütz E, Christians U, Grupp C, Sattler B, et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. Transplant Proc 1996;28:3175-6.
15. Salm P, Taylor PJ, Clark A, Balderson GA, Grygotis A, Norris RLG, et al. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus (FK506) to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit 1997;19:694-700.
16. Kino T, Inamura F, Sakai K, Nakahara K, Goto T, Okuhara M, et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987;19(Suppl 6):36-9.
17. Gonschior A-K, Christians U, Winkler M, Schiebel HM, Linck A, Sewing K-F. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit 1995;17:504-10.
18. Taylor PJ, Jones A, Balderson GA, Lynch SV, Norris RLG, Pond SM. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 1996;42:279-85.
19. Büttner J. Reference materials and reference methods in laboratory medicine: a challenge to international cooperation. Eur J Clin Chem Clin Biochem 1994;32:571-77.
20. Taylor PJ, Hogan NS, Lynch SV, Johnson AG, Pond SM. An improved method for the therapeutic drug monitoring of tacrolimus (FK506) using tandem mass spectrometry [Technical Brief]. Clin Chem 1997;43:2189-90.
21. Krouwer JS, Rabinowitz R. How to improve estimates of imprecision. Clin Chem 1984;30:290-2.
22. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
24. Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T, et al. Physiochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;5(Suppl 6):11-6.
25. McMaster P, Mirza DF, Ismail T, Vennarecci G, Patapis P, Mayer AD. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-5.
26. Abbott Laboratories. Reagent pack insert for Tacrolimus II. Abbott Park, IL: Abbott Laboratories, 1996:4.